Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients

被引:64
作者
Freeman, RB
Paya, C
Pescovitz, MD
Human, A
Dominguez, E
Washburn, K
Blumberg, E
Alexander, B
Heaton, N
机构
[1] New England Med Ctr Transplant Surg, Boston, MA 02111 USA
[2] Mayo Clin, Rochester, MN USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
[4] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada
[5] Univ Nebraska, Ctr Med, Univ Med Associates, Omaha, NE 68182 USA
[6] Univ Texas, Hlth Sci Ctr, UTHSCSA Organ Transplant, San Antonio, TX 78285 USA
[7] Hosp Univ Penn, Philadelphia, PA 19104 USA
[8] Duke Univ, Med Ctr & Hlth Syst, Dept Pathol, Clin Labs,Clin Microbiol Labs, Durham, NC USA
[9] Kings Coll Hosp London, Liver Transplant Dept, London, England
关键词
cytomegalovirus; solid organ transplantation; prophylaxis; valganciclovir;
D O I
10.1097/01.TP.0000142619.01510.A5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Cytomegalovirus (CMV) D+/R- solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease; however, other risk factors in these patients have not been delineated. Methods. We examined 20 demographic and clinical variables for their association with the development of CMV disease, as defined by an independent endpoint committee (IEC) andalso by the investigator (investigator treated [IT]), or CMV viremia within 12 months of transplant in D+/R- transplant recipients who received prophylaxis with valganciclovir or oral ganciclovir for 100 days. Results. Recipients with low creatinine clearance (C-cr,<40 mL/min) at screening had a significantly increased hazard of developing IEC-defined CMV disease (hazards ratio [HR] =4.28, confidence interval [CI] 1.69,10.83). Females were twice as likely (HR=2.19, CI.21, 3.99) to develop IEC-defined CMV disease thin males. These variables were associated with an increased risk of IEC-defined CMW disease in time-dependent models. Recipients with blood group A were also more likely to develop IEC-defined CMV disease than those with group O (HR=2.36 CI 1.24,4.51) in the logistic regression model only. Prophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression regimen were not associated with IEC-defined CMV disease. Female sex was the only variable associated with the development of CMV viremia (odds ratio [OR] = 1.65; CI 1.03, 2.65) and IT CMV disease (OR= 1.78; CI 1.08,2.93). Conclusions. Low C-cr at screening and blood type A are risk factors for IEC-defined CMV disease, and female sex was a risk factor for IEC- and IT-defined CMV disease and viremia in high-risk SOT recipients. These variables should perhaps be considered when optimizing treatment.
引用
收藏
页码:1765 / 1773
页数:9
相关论文
共 26 条
[1]   PROSPECTIVE RANDOMIZED TRIAL OF EFFICACY OF GANCICLOVIR VERSUS THAT OF ANTICYTOMEGALOVIRUS (CMV) IMMUNOGLOBULIN TO PREVENT CMV DISEASE IN CMV-SEROPOSITIVE HEART-TRANSPLANT RECIPIENTS TREATED WITH OKT3 [J].
AGUADO, JM ;
GOMEZSANCHEZ, MA ;
LUMBRERAS, C ;
DELGADO, J ;
LIZASOAIN, M ;
OTERO, JR ;
RUFILANCHAS, JJ ;
NORIEGA, AR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1643-1645
[2]  
Ahsan N, 1997, CLIN TRANSPLANT, V11, P633
[3]  
BOLAND GJ, 1993, CLIN EXP IMMUNOL, V94, P306
[4]   The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients [J].
Cavdar, C ;
Sayan, M ;
Sifil, A ;
Artuk, C ;
Yilmaz, N ;
Bahar, H ;
Camsari, T .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2003, 37 (01) :71-76
[5]   Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients [J].
Evenepoel, DRJKP ;
Maes, BD ;
Coosemans, W ;
Pirenne, J ;
Vanrenterghem, YFC .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (04) :1164-1170
[6]  
GODFREY K, 1992, MED USES STAT
[7]  
Hebart Holger, 2000, Herpes, V7, P13
[8]   PREVALENCE OF INVASIVE CYTOMEGALOVIRUS DISEASE WITH ADMINISTRATION OF MUROMONAB CD-3 IN PATIENTS UNDERGOING ORTHOTOPIC LIVER-TRANSPLANTATION [J].
HOOKS, MA ;
PERLINO, CA ;
HENDERSON, JM ;
MILLIKAN, WJ ;
KUTNER, MH .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (05) :617-620
[9]   Estradiol enhances gene delivery to human breast tumor cells [J].
Jain, PT ;
Gewirtz, DA .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (10) :709-714
[10]   THE USE OF VACCINES IN RENAL-FAILURE [J].
JOHNSON, DW ;
FLEMING, SJ .
CLINICAL PHARMACOKINETICS, 1992, 22 (06) :434-446